BJ Bioscience Inc. is a biotechnology company dedicated to the research and development of innovative drugs. It is created by returnees with many years of experience in research and development of innovative drugs and complimentary expertise, including a review expert of National Key Innovative Drug R&D Projects, the National Health Commission of China. Based on its top notch trade secret protected antibody generation and screening technology, BJ Bioscience focuses its R&D in cancer, infectious and autoimmune diseases. Key members of the company's R&D team have many years of experience in research and development and management of antibody drugs from key national scientific research institutions, domestic and multinational pharmaceutical companies especially European and American multinational companies.
With a global perspective of pharmaceutical R&D and supported by strong capital, BJ Bioscience has built its global presence at the beginning of its inception. It has two discovery laboratories globally, one in Hangzhou, China and one in San Francisco, USA. Such global perspective and presence enables the company to realize globally the full range of talents, technology, management and capital market in the early stage of its entrepreneurship and lays a solid foundation for its global positioning and development.
Based on its top notch trade secret protected antibody generation and screening platform, BJ Bioscience is committed to the development of next generation of innovative biopharmaceuticals for the treatment of diseases related to the immune system such as cancer, autoimmune diseases and infections. By leveraging its platform, expertise, and network in China and the US, BJ Bioscience strives to speed up translation of innovation to therapeutics and provide innovative and high quality biopharmaceuticals to patients with unmet medical needs.